-
Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst
Wednesday, August 27, 2025 - 2:43pm | 608Read More...Summit Therapeutics Inc (NASDAQ:SMMT) and Akeso said ivonescimab, a PD-1xVEGF bispecific antibody, can extend patients' lives for EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) progressed after EGFR-TKI treatment. Akeso said that the clinical trial...
-
Why Is Summit Therapeutics Stock Trading Higher On Monday?
Monday, April 28, 2025 - 1:00pm | 653Read More...Summit Therapeutics Inc. (NASDAQ:SMMT) on Friday noted that Akeso, Inc. announced the Chinese Health Authorities, the National Medical Products Administration (NMPA) approved ivonescimab for a second indication based on the results of the Phase 3 trial, HARMONi-2 or AK112-303. On Friday,...
